FDA Approves TherOx’s SuperSaturated Oxygen Heart Attack Therapy

 
• By Reed Miller

Clinical trials have shown that SuperSaturated Oxygen Therapy (SSO2 Therapy) reduces the size of myocardial infarcts in the regions of the heart-muscle perfused by the patient’s left anterior descending coronary artery immediately following stenting.

FDA approved background, 3D rendering, blue street sign

More from Approvals

More from Policy & Regulation